Cell invasion through connective tissue matrices requires a proteinase cascade, the controlling feature of which is regulated activation of plasminogen by urokinase type plasminogen activator (u-PA). U-PA is synthesized as a minimally active single chain molecule (scu-PA), but can be cleaved to an active two chain form (tcu-PA) by plasmin. This circular, but fundamental process has been puzzling: First, if tcu-PA is required to activate plasminogen, but plasmin is required to activate scu- PA, how does the process start? Second, because this is a """"""""positive feedback loop."""""""" how does the process stop? Furthermore, tcu-PA on the cell u-PA receptor (u-PAR) is efficiently inhibited by plasminogen activator inhibitor (PAI). so how do cells invade through PAI-rich environments? We have used a form of scu-PA, glu158-scu-PA, not cleaved by plasmin to demonstrate that i) scu-PA exhibits enzymatic activity, and that when it and plasminogen are bound to their respective cell surface binding sites, plasmin is generated 100-fold more efficiently than if the reactants are in solution; this activation is carried out by single chain, not two chain u-PA. Hence scu-PA can initiate the process; and ii) scu-PA, in solution binds reversibly to PAI-2, whereas scu-PA on the u-PA receptor is not inhibited. Hence plasminogen activation requires that scu-PA first dissociate from PAI-2, then bind to cell surface receptor to express enzymatic activity even in the presence of excess PAI-2. This probably influences the initiation process, and allows cells to invade through PAI- rich environments. In this application we will focus on testing, each component of the initiating steps of cell surface plasminogen activation. Specifically, we propose to determine. 1) whether the reversible binding of scu-PA to PAI-2 and/or u-PAR has a regulatory role in the initiation of cell surface plasminogen activation (i.e.. is the partitioning of scu-PA between PAI 2 and u-PAR a primary determinant of cell surface plasminogen activation?) 2) The mechanism by which plasminogen is activated by scu-PA 100-fold more efficiently on the monocyte cell surface than in solution. Is it due to an effect on K(m), K(cat), the nature of plasminogen as a substrate, or a combination of these? 3) By analogy to plasminogen activation on fibrin clots whether the enzymatic activity of plasmin plays a role in accelerating plasminogen activation at the cell surface. This work should define regulatory mechanisms for initiating this fundamental property of invading cells.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL043506-13
Application #
2668677
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1983-08-01
Project End
2002-02-28
Budget Start
1998-03-01
Budget End
2002-02-28
Support Year
13
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Li, Shih-Hon; Gorlatova, Natalia V; Lawrence, Daniel A et al. (2008) Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem 283:18147-57
Barker-Carlson, Karen; Lawrence, Daniel A; Schwartz, Bradford S (2002) Acyl-enzyme complexes between tissue-type plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem 277:46852-7
Schwartz, B S; Espana, F (1999) Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation. J Biol Chem 274:15278-83
Lumelsky, N L; Schwartz, B S (1997) Protein kinase C in erythroid and megakaryocytic differentiation: possible role in lineage determination. Biochim Biophys Acta 1358:79-92
Lumelsky, N L; Schwartz, B S (1996) Protease inhibitors induce specific changes in protein tyrosine phosphorylation that correlate with inhibition of apoptosis in myeloid cells. Cancer Res 56:3909-14
Goldman, I L; Kopelberg, M; Debaene, J E et al. (1996) Antiplatelet activity in onion (Allium cepa) is sulfur dependent. Thromb Haemost 76:450-2
Manchanda, N; Schwartz, B S (1995) Interaction of single-chain urokinase and plasminogen activator inhibitor type 1. J Biol Chem 270:20032-5
Schwartz, B S (1994) Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism. J Biol Chem 269:8319-23
Schwartz, B S; Bradshaw, J D (1992) Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. Correlation with production of the protein. J Biol Chem 267:7089-94
Manchanda, N; Schwartz, B S (1991) Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 266:14580-4